Notably, we observed that MTR-OralGem administration markedly increased the percentages of tumor-infiltrating CD3+CD8+PD-1+ and CD3+CD4+PD-1+ T cells, compared to MTD-Gem treatment (Figure 6H,I). The gene discussed is CD8A; the disease is neoplasm.